Obesity Medicine Board Review Questions

Obesity Medicine Board Review QuestionsObesity Medicine Board Review QuestionsObesity Medicine Board Review Questions
  • Home
  • Blog
  • Online QBank
  • Shop
  • Bio
  • Contact Me
  • Book Updates
  • More
    • Home
    • Blog
    • Online QBank
    • Shop
    • Bio
    • Contact Me
    • Book Updates

Obesity Medicine Board Review Questions

Obesity Medicine Board Review QuestionsObesity Medicine Board Review QuestionsObesity Medicine Board Review Questions
  • Home
  • Blog
  • Online QBank
  • Shop
  • Bio
  • Contact Me
  • Book Updates

2023 Edition Book Updates

Obesity medicine is an ever-changing speciality which is exciting but also requires frequent updates. 2023 was a year of new medications, treatments, and guidelines. All updates discussed below have been incorporated into the 2024 edition. 



Obesity Medicine Board Review Questions

These are updates to the 2023 edition of the blue book since publication. A short description is provided in the left hand column, whereas the right hand column refers to the question numbers affected.

BP Cuff Size

32

In the question stem, the patient's arm circumference should be 36 cm.

Aspire Assist® Device

102, 150

The Aspire Assist® Device was electively discontinued in 2022 due to financial constraints, not safety or efficacy. This device may show up on test day (contraindications, complications, etc.) given that patients may have had this procedure done, but would not be the preferred weight-loss treatment option anymore given its lack of availability.

Staged Pediatric Approach to Obesity

130, 169, 197

The 2023 updated AAP guidelines have now replaced the staged approach to pediatric obesity. This is a big change to the long-tested and utilized prior recommendations. Check back here for updated replacement questions or subscribe to the blog to be notified when these questions become available. Review new guidelines here.

Surgical Indications

140

Answer choice B is also a surgical candidate. Answer D is likely still the best option given a number of comorbidities, but both are current surgical candidates.

Semaglutide Indication

146

Semaglutide (Wegovy ® ) is now approved for chronic weight-management in those 12 years and older. 

Gastric Balloon Updates

176

ReShape™ (dual-balloon system) has been bought out by Orbera™ (single-balloon system), who has since discontinued ReShape™ production. Also, Spatz 3™ has been approved (first adjustable balloon that can stay in place 8 months instead of 6), as well as Obalon™ (first swallowable balloon, with up to 3 balloons being deployed at 2 week intervals) is now approved in those > 22 years old. 

Plenity Increases Satiety

179

This question states in the explanation that cellulose and citric acid hydrogel decreases satiety. It should read as: Cellulose and citric acid hydrogel (brand name Plenity®) is a volume-occupying treatment for those with a BMI of 25-40kg/m2. It is taken before meals to increase satiety. 


Obesity Medicine Practice Tests

These are updates to the 2023 edition of the red book since publication. The right hand column refers to the question numbers affected.

Semaglutide Indication

46

See comments above.

Staged Pediatric Approach to Obesity

57, 145, 294

See comments above.

Androgenetic alopecia

62

Answer D should be androgenic alopecia (not adrenergic)

Aspire Assist® Device

88

See comments above.

Gastric Balloon Updates

105

See comments above.

Please note, that given the recency of these updates, they may not affect the upcoming testing window.

  • Privacy Policy
  • Terms and Conditions

Obesity Medicine Board Review Questions

Copyright © 2025 Obesity Medicine Board Review Questions, LLC - All Rights Reserved.

Powered by

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

Accept